Terremoto Biosciences Raises $108M Series C to Advance Covalent Small-Molecule Medicines

Terremoto Biosciences isn’t making noise for the sake of it. This is controlled force, the kind that builds quietly in the lab and then shows up all at once in the numbers. A $108M Series C does not just land, it signals that something underneath is starting to move with intent.

RA Capital Management led the round, joined by Deep Track Capital, Osage University Partners, and BeOne Medicines, with OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management leaning back in like seasoned bettors who have seen this movie before and liked the ending.

Now zoom in. This is not another biotech swinging wildly at broad targets and hoping biology cooperates. Terremoto is working the fine print of chemistry, building covalent small molecules designed to lock onto targets with intent. Lysine based covalent chemistry is their lane, and they are driving it like they paved the road themselves.

Charles Baum, M.D., Ph.D., CEO, is steering the operation with the kind of pattern recognition you only get from years inside the oncology arena. Peter Thompson, M.D., Co-founder and Board Chair, still holds it down, which tells you continuity is not a talking point here, it is embedded. James Christensen, Ph.D., President and Head of R&D, is pushing the science forward, translating deep chemistry into something that might actually matter in a clinic.

The pipeline is where the story tightens. TER 2013 is already in Phase 1, going after tumors with PIK3CA, AKT, or PTEN alterations. That is not a niche, that is a crowded battlefield where precision is the only way to win. Then you have TER 4480 lining up for HHT, a rare disease with no approved therapies. Different markets, same philosophy. Hit the target clean, or do not swing.

$108M here is not just fuel, it is validation of a thesis. Build molecules that bind with intention, not hope. Advance programs that are selective enough to matter when biology starts pushing back. And surround it with investors who understand that real breakthroughs rarely look obvious in the early innings.

There is a lesson buried in all of this for anyone building. Capital does not chase noise forever. It gravitates toward teams that can articulate exactly where they are going and why their approach is structurally different. Terremoto is not trying to be louder. They are trying to be sharper. And in a market full of volume, sharp tends to travel further.